Recently, we completed a phase II clinical trial evaluating thecombination of the HDAC inhibitor vorinostat with tamoxifen in 43 patients withadvanced breast cancer who had previous progressed on aromatase inhibitors [9]. This evidence concerns the gene HDAC9 and breast carcinoma.